Cosmo Pharmaceuticals N.V.

COPN

NL0011832936

Pharmaceuticals

Market Closed - Swiss Exchange Other stock markets 11:31:42 2025-06-24 am EDT			5-day change	1st Jan Change
57.20 ^CHF	+1.60%		-2.05%	-10.20%

Apr. 29	Swiss Stocks Advance; Cosmo Shares Fall on Acne Vulgaris Drug Setback	MT
Apr. 29	Cosmo Pharmaceuticals Affirms FY25 Guidance After Winlevi Setback	MT

Cosmo Pharmaceuticals Licenses Acne Treatment Winlevi to Hikma in Middle East, North Africa

Published on 10/02/2023 at 03:26, updated on 10/02/2023 at 03:28

This article is reserved for members

Unlock the article: REGISTER NOW!

100% Free Registration

Already a customer? Log In

Latest news about Cosmo Pharmaceuticals N.V.

Swiss Stocks Advance; Cosmo Shares Fall on Acne Vulgaris Drug Setback	Apr. 29	MT
Cosmo Pharmaceuticals Affirms FY25 Guidance After Winlevi Setback	Apr. 29	MT
Cosmo Pharmaceuticals to Seek EU Panel's Re-examination of Acne Vulgaris Drug	Apr. 29	MT
Cosmo Pharmaceuticals N.V. Appoints Federico Sommariva as Chief Legal Counsel	Apr. 01	CI
Cosmo Pharmaceuticals Names Chief Legal Counsel	Apr. 01	MT
Cosmo Pharmaceuticals N.V. Reports Earnings Results for the Full Year Ended December 31, 2024	Mar. 21	CI
Cosmo Pharmaceuticals N.V., Q4 2024 Earnings Call, Mar 06, 2025	Mar. 06
Cosmo Pharmaceuticals N.V. Announces the Appointment of Andrea Cherubini as Chief AI Officer	Feb. 11	CI
Swiss Stocks Begin Week Upbeat; KOF Global Economic Barometers Improve	Feb. 10	MT
Indian Indices Extend Losing Streak on Monday as Trump's Tariff Threats Weigh on Sentiment	Feb. 10	MT
Glenmark, Cosmo Pharmaceuticals Get UK Regulator's Nod to Market Acne Treatment Winlevi in UK	Feb. 10	MT
Cosmo Pharmaceuticals Partnership Obtains UK Marketing Permit for Winlevi	Feb. 10	MT
Cosmo Pharmaceuticals N.V. and Glenmark Pharmaceuticals Limited Announce UK MHRA Approval of Winlevi for Treatment of Acne	Feb. 10	CI
Cosmo Pharmaceuticals Logs Growth in FY24 Revenue	Jan. 09	MT
Cosmo Pharmaceuticals N.V. Appoints Dominika Spilarova as Chief Strategy Officer, Effective January 10, 2025	Dec. 13	CI
Cosmo Pharmaceuticals Names First Chief Strategy Officer	Dec. 12	MT
Cosmo Pharmaceuticals N.V. Announces Chief Financial Officer Changes	24-10-11	CI
Cosmo Pharmaceuticals CFO to Shift to New Role; Successor Named	24-10-11	MT
Cosmo Pharmaceuticals Unit's AI Endoscopy System Secures US FDA Clearance	24-07-31	MT
Cosmo Pharmaceuticals N.V., H1 2024 Earnings Call, Jul 24, 2024	24-07-24
Cosmo Pharmaceuticals' H1 Attributable Profit, Revenue Soars	24-07-24	MT
Cosmo Pharmaceuticals N.V. Reports Earnings Results for the Half Year Ended June 30, 2024	24-07-23	CI
Switzerland's Cosmo Pharmaceuticals Receives Drug Registration Certificate for Lumeblue in China	24-06-18	MT
Cosmo Pharmaceuticals N.V. Announces Executive Changes at the Upcoming Annual General Meeting on 24 May 2024	24-04-26	CI
Cosmo Pharmaceuticals Names New CEO, Chairman	24-04-25	MT

Chart Cosmo Pharmaceuticals N.V.

Duration

Period

COPN: Dynamic Chart

Cosmo Pharmaceuticals N.V. is a pharmaceutical company. The Company is focused on gastrointestinal (GI) diseases and dermatology. Its development pipeline is focused on Breezula (clascoterone), GI Genius, Methylene blue MMX, Aemcolo, CB-03-10, CB-01-33 (colesevelam), and CB-01-35. The Company's developed products include Lialda/Mezavant/Mesavancol and Uceris/Cortiment, for the treatment of ulcerative colitis; GI Genius, which uses artificial intelligence to aid the detection of colorectal polyps during colonoscopy; Eleview, a submucosal injectable composition for use in gastrointestinal endoscopic procedures; Aemcolo for the treatment of travelersâ diarrhea (TD), Methylene Blue MMX, which is a new diagnostic drug to improve precancerous and cancerous lesion detection during colonoscopy and Winlevi for the treatment of acne. Its therapeutic focus is on the oral and endoscopic treatment of colon diseases.

Employees

322

Sector

Pharmaceuticals

Calendar

Jun. 30 - Investor Day

More about the company